Karen Anderson, MD
Psychiatry · Baltimore, MDNPI 1891718359
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $98,676 of the $117,475 with a category attached, or 84.0%. 14 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 40.8% of the total. 2025 is the largest year on record at $31,419, 2.8 times the $11,282 reported in 2019. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 94 payments — averaging $1249.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$48K
- Sanofi US Services Inc.$24K
- F. Hoffmann-la Roche AG$17K
- H. Lundbeck A S$9K
- Eli Lilly$8K
- Roche Products Limited$6K
- plus $5K from 8 others
Across 38 payments — averaging $26,273 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$668K
- F. Hoffmann-la Roche AG$260K
- Alnylam Pharmaceuticals Inc.$30K
- PTC Therapeutics, Inc.$29K
- Genentech, Inc.$12K
- Neurocrine Biosciences, Inc.$750
What the payments were for
- Consulting fees$98,67684%
- Speaking & faculty fees$9,9518%
- Travel & lodging$6,5666%
- Food & beverage$1,9312%
- Education$3520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 36 | $47,897 |
| Sanofi US Services Inc. | 9 | $24,065 |
| F. Hoffmann-la Roche AG | 17 | $17,160 |
| H. Lundbeck A S | 4 | $8,576 |
| Eli Lilly | 6 | $8,447 |
| Roche Products Limited | 6 | $5,977 |
| Sage Therapeutics, LLC | 6 | $3,533 |
| Vertex | 4 | $1,307 |
| PTC Therapeutics, Inc. | 1 | $233 |
| Novartis | 1 | $104 |
| Genentech USA, Inc. | 1 | $91 |
| Neurocrine Biosciences, Inc. | 1 | $47 |
| Abbott | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$23,605
- Austedo XR$12,348
- Tamiflu$6,300
- OCREVUS$6,300
- EVRYSDI$6,300
- Enspryng$6,300
- Non-Covered Product$2,615
How this compares
$117,475 in reported general payments places this provider in the 95th percentile of 851 psychiatry providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 22 | $223,366 |
| IngrezzaValbenazine Tosylate | 18 | $185,314 |
| NuplazidPimavanserin Tartrate | 12 | $63,915 |
| Clonazepam | 59 | $1,804 |
| Quetiapine Fumarate | 85 | $1,629 |
| Clozapine | 24 | $1,213 |
| Escitalopram Oxalate | 51 | $1,170 |
| Mirtazapine | 30 | $1,013 |
| Duloxetine Hcl | 40 | $955 |
| Bupropion XlBupropion Hcl | 43 | $932 |
| Lorazepam | 32 | $868 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $659 |
| Hydroxyzine Hcl | 15 | $575 |
| RivastigmineRivastigmine Tartrate | 19 | $415 |
| Trazodone Hcl | 32 | $383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $47,897 | $223,36622 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $47 | $185,31418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 851 psychiatry providers in Maryland.
Other psychiatry in Baltimore
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Robert LehmanBaltimore$140K
- Orlando DavisBaltimore$104K
- Akira SawaBaltimore$69K
- Paul RosenbergBaltimore$66K
- Adam KaplinBaltimore$62K
- Marc FishmanBaltimore$59K
- David NeubauerBaltimore$59K
- Chiadikaobi OnyikeBaltimore$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.